Background Antitachycardia pacing (ATP) provides safe and painless termination of reentrant ventricular arrhythmias in patients with implantable cardioverter defibrillator (ICDs), improving their quality of life. Established predictors of ATP responsiveness are not well known; only longer ventricular tachycardia (VT) cycle length and higher ejection fraction have been found to predict ATP success. Objective To investigate clinical and ECG predictors of ATP response in ICD patients with monomorphic VT. Methods The ICD clinic database was searched for monomorphic VT events requiring ICD therapy in patients with ischemic or non‐ischemic cardiomyopathy. Each patient's first ICD encounter for VT was assessed. Patient demographics, clinical characteristics, VT rate, and ATP responsiveness (always, sometimes, and never successful) were recorded. An ECG was analyzed for QRS morphology and duration. Data was assessed for predictors of ATP responsiveness. Results In 527 patients, characteristics associated with always successful ATP included ACE‐I/ARB therapy and slower VT rate (never successful ATP 197 ± 28 bpm, sometimes successful ATP 190 ± 27 bpm, always successful ATP 183 ± 22 bpm, P < .0001). Secondary prevention indication, amiodarone therapy, and longer QRS duration were associated with ATP failure. After multivariate analysis, only faster VT rate and amiodarone therapy were predictive of ATP failure. Conclusions Neither QRS morphology nor duration was predictive of ATP success. Slower VT rate was predictive of repeated ATP responsiveness. Amiodarone therapy, which is known to increase VT cycle length, interestingly was associated with ATP failure for unclear reasons. More individualized and possibly more aggressive ATP programming may be warranted in patients on amiodarone.
CVD is a major cause of morbidity and mortality worldwide, responsible for nearly a third of all deaths. In US, 85.6 million Americans are living with CVD, including 15.5 million with coronary heart disease (CHD). Heart disease (HD) specifically is responsible for approximately one in every seven American deaths, taking 370,213 lives per year. Perhaps even more striking than CHD’s mortality is its preventability. The CDC estimates that 34% of deaths caused by HD could potentially be prevented with modifiable risk factors including hypertension, hyperlipidemia, diabetes, smoking, poor diet, and sedentary lifestyle. By comparing the mortality of CVD and CHD in the US, Europe, and the United Kingdom (UK), we aim to gain a better understanding of the CVD burden and economic cost. Methods: We conducted a literature review of the most recent epidemiological data for US, Europe, and UK to compare mortality due to CVD and CHD between these three regions. Data sources for US include the AHA and CDC. Data for Europe was obtained from the European Society of Cardiology, following the World Health Organization’s definition of 53 states as the European region. The UK is included as it was considered independently in this study. Data for the UK was published by the British Heart Foundation. Results: The comparison of data shows that high mortality is evident in all represented countries and regions with a highest percent of CVD of total deaths in Europe as compared to US (45% vs 30.8%) and CHD (20% vs 14.2%). Very similar findings according annual mortality are evident comparing US to UK for CVD (30.8% vs 28%) and for CHD (14.2% vs 13%). The treatment for CVD is increasing over time, with prescriptions and operations costs around 6.8 billion in England, the majority spend on secondary care. CDC data in US show that Americans suffer 1.5 million heart attacks and strokes each year, which contributes more than $320 billion in annual healthcare costs and lost productivity. By 2030, this cost is projected to rise to $818 billion, while lost productivity costs to $275 billion. Conclusions: Although there is some variation between Europe as a group of 53 countries compared to the US and UK, it is clear that CVD has a major impact on mortality in all three regions studied. Improved prevention of CVD, including heart disease, has the potential to save lives around the globe and to reduce economic burden.
In the last decade, neuromodulation via baroreflex activation therapy (BAT) and vagus nerve stimulation (VNS) has emerged as an innovative approach for the treatment of heart failure with reduced ejection fraction (HFrEF). A review of the literature was conducted to examine the latest efficacy and safety data on neuromodulation for the treatment of HFrEF. Two independent researchers searched the PubMed, clinicaltrials.org, and the Cochrane databases for the most recent data on BAT and VNS published between 2013 and 2019. A total of nine studies were identified. BAT and VNS therapy consistently improved subjective heart failure parameters including New York Heart Association class and Minnesota Living with Heart Failure Questionnaire. Improvements in objective cardiac parameters such as left ventricular ejection fraction (LVEF) were less consistently seen; however, where present, ranged from +3% to +6%, in line with improvements seen after other guideline directed therapy such as left ventricular assist device (LVAD). Benefits of BAT showed a predilection for patients without cardiac resynchronization therapy (CRT) and efficacy of VNS therapy varied with device type. The clinical application of BAT and VNS was found to be limited due to low-powered data, inconsistencies in study design, short-term follow-up and lack of diversity in patient recruitment. Well-powered studies with consistent design, longer follow-up and diverse populations are warranted before BAT and VNS can be incorporated into heart failure guidelines and clinical practice.
Recipients of IAS utilize the healthcare system more frequently following an IAS than patients not experiencing a shock. This increased utilization results in higher costs of treating IAS patients during the 12 months postimplant.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.